HC Wainwright Forecasts Merus' Q2 Earnings (NASDAQ:MRUS)

Merus (NASDAQ:MRUS - Free Report) - Investment analysts at HC Wainwright reduced their Q2 2025 earnings per share estimates for Merus in a report released on Thursday, May 8th. HC Wainwright analyst A. Fein now anticipates that the biotechnology company will earn ($1.28) per share for the quarter, down from their prior estimate of ($1.24). HC Wainwright has a "Buy" rating and a $85.00 price target on the stock. The consensus estimate for Merus' current full-year earnings is ($3.85) per share. HC Wainwright also issued estimates for Merus' Q3 2025 earnings at ($1.19) EPS, Q4 2025 earnings at ($1.29) EPS, FY2025 earnings at ($5.15) EPS, FY2026 earnings at ($4.86) EPS, FY2027 earnings at ($3.60) EPS and FY2028 earnings at ($1.79) EPS.

MRUS has been the subject of several other research reports. Guggenheim reissued a "buy" rating and issued a $109.00 target price on shares of Merus in a research report on Friday, March 28th. Piper Sandler started coverage on shares of Merus in a research report on Thursday, February 13th. They issued an "overweight" rating and a $84.00 target price for the company. Wells Fargo & Company dropped their target price on shares of Merus from $91.00 to $89.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. Bank of America dropped their target price on shares of Merus from $73.00 to $70.00 and set a "buy" rating for the company in a research report on Monday, March 10th. Finally, William Blair reissued an "outperform" rating on shares of Merus in a research report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, fourteen have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $85.15.

Merus Trading Down 1.3%

NASDAQ MRUS traded down $0.52 during trading hours on Monday, reaching $40.40. 655,348 shares of the company traded hands, compared to its average volume of 717,961. The stock has a market capitalization of $2.80 billion, a PE ratio of -10.23 and a beta of 0.94. Merus has a 12 month low of $33.19 and a 12 month high of $61.61. The company has a 50 day moving average of $43.43 and a two-hundred day moving average of $43.96.

Merus (NASDAQ:MRUS - Get Free Report) last released its quarterly earnings results on Wednesday, May 14th. The biotechnology company reported ($1.40) earnings per share for the quarter, missing analysts' consensus estimates of ($1.17) by ($0.23). The company had revenue of $26.49 million for the quarter, compared to analyst estimates of $7.82 million. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%.

Institutional Investors Weigh In On Merus

Several institutional investors have recently bought and sold shares of MRUS. GAMMA Investing LLC lifted its holdings in Merus by 2,153.6% in the first quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company's stock worth $27,000 after purchasing an additional 603 shares during the period. State of Wyoming acquired a new stake in Merus in the fourth quarter worth about $48,000. Wells Fargo & Company MN lifted its holdings in Merus by 27.3% in the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock worth $59,000 after purchasing an additional 300 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Merus in the fourth quarter worth about $60,000. Finally, Avior Wealth Management LLC acquired a new stake in Merus in the fourth quarter worth about $76,000. Institutional investors and hedge funds own 96.14% of the company's stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.